The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilars: Still Waiting for Promise to Materialize

Biosimilars: Still Waiting for Promise to Materialize

January 17, 2018 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

However, a disconnect exists between what patients see in costs and what manufacturers receive for their medication. Much of that difference derives from pharmacy benefit managers (PBMs; see also “Rheumatologists’ Frustrations with PBMs Aired at Annual Meeting,” The Rheumatologist, January 2017, p. 42). Dr. Huffstutter and other speakers at the ACR/ARHP Annual Meeting noted that PBMs are a disruptive force in the biosimilar marketplace, preventing the competition that could lead to lower costs.

You Might Also Like
  • The Science Behind Biosimilars
  • Biosimilars: How Do They Affect Patient Care & Safety?
  • Biosimilars to Raise Unique Questions
Explore This Issue
February 2018

On Nov. 2, 2017, shortly before the ACR/ARHP Annual Meeting started, the Centers for Medicare & Medicaid Services released its Final Policy, Payment, and Quality Provisions in the Medicare Physician Fee Schedule for Calendar Year 2018.2 This policy changed a previous proposal that biosimilar products relying on a common reference product’s biologics license application would be grouped into the same payment calculation for determining a single average sales price payment limit. Instead, the new policy will pay for each biosimilar according to its distinct individual average price.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR plans to release a white paper on biosimilars and interchangeability in the near future, reported Angus Worthing, MD, chair of ACR’s Government Affairs Committee. The ACR has also advocated for a national policy on substitution of interchangeable biologics that would require notifying the patient and physician prior to the substitution or within 24 hours. A total of 36 states now have laws in place with similar provisions.


Larry Beresford is a freelance medical journalist in Oakland, Calif.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. U.S. Food & Drug Administration. Considerations in demonstrating interchangeability with a reference product: Draft guidance for industry. 2017 Jan.
  2. Centers for Medicare & Medicaid Services. Final policy, payment and quality provisions in the Medicare physician fee schedule for calendar year 2018. 2017 Nov 2.
FDA-Approved Biosimilars to Rheumatology Drugs (as of December 2017)
Biosimilar Reference Product
adalimumab-atto (Amjevita)

adalimumab (Humira)

adalimumab-adbm (Cyltezo) adalimumab (Humira)
etanercept-szzs (Erelzi) etanercept (Enbrel)
infliximab-abda (Renflexis) infliximab (Remicade)
infliximab-dyyb (Inflectra) infliximab (Remicade)
infliximab-qbtx (IXIFI) infliximab (Remicade)

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates, Meeting Reports Tagged With: 2017 ACR/ARHP Annual Meeting, ACR/ARHP Annual Meeting, Biologics & Biosimilars, biosimilar, drug pricing, Drug Updates, interchangeabilityIssue: February 2018

You Might Also Like:
  • The Science Behind Biosimilars
  • Biosimilars: How Do They Affect Patient Care & Safety?
  • Biosimilars to Raise Unique Questions
  • Biosimilars Great Debate: To Switch or Not?

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.